Innovation Fund Boosts Commercialization of Purdue Technologies
News Jan 31, 2013
The Purdue Research Foundation-managed Trask Innovation Fund is a technology development program to assist faculty who have disclosed a discovery to the Purdue Office of Technology Commercialization.
"The Trask Innovation Fund provides critical financial support to Purdue researchers who have patented a technology but need to develop a prototype or finalize research data that supports the discovery’s move to the public," said Joseph B. Hornett, senior vice president, treasurer and COO of the Purdue Research Foundation.
The 10-member Trask Innovation Advisory Council is composed of external business executives and representatives from the Purdue Research Foundation, Purdue University Office of the Vice President for Research and Purdue faculty researchers.
"The process is competitive and the recipients must demonstrate how the discovery will meet a public need, how soon the technology can be commercialized, and how the Trask funds will help the researcher advance its development," said Richard O. Buckius, Purdue's vice president for research and co-director of the Trask Advisory Council.
Project managers from the Purdue Office of Technology Commercialization collaborate with Purdue researchers to move their discoveries through the patent and commercialization process.
"One of our primary goals is to encourage and support the development of new products that have commercial potential," said Elizabeth Hart-Wells, assistant vice president of the Purdue Office of Technology Commercialization and co-director of the Trask Advisory Council. "Each of our project managers is specialized in a specific discipline, and they work directly with researchers to protect Purdue’s intellectual property, and to translate and ultimately license a new technology to appropriate industry partners."
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Studying Ebola-Host Cell Interaction Helps Find Targets for Antiviral DrugsNews
In some ways, the Ebola virus operates like a vampire; only after it is politely invited in to a host cell does it take up the task of destroying everything in its path. In a new study researchers seek to elucidate quantitatively the biomechanical mechanism of Ebola-host cell interaction, providing potential new targets for antiviral drug development.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018